3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Specimen Handling
336
Magnetic Resonance Spectroscopy
333
Radiotherapy
315
Cyclophosphamide
295
pembrolizumab
282
Cisplatin
266
Carboplatin
245
Drug Therapy
237
Blood Specimen Collection
233
Biopsy
206
Bevacizumab
187
Gemcitabine
177
venetoclax
172
Radiosurgery
169
Capecitabine
165
Oxaliplatin
163
fludarabine
160
Nivolumab
156
Paclitaxel
155
Standard of Care
137
Surveys and Questionnaires
131
Surgical Procedures, Operative
130
Dexamethasone
127
Fluorouracil
125
Docetaxel
113
tislelizumab
110
Rituximab
110
Cytarabine
104
atezolizumab
101
Azacitidine
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
OTHER
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled